
Abbott Laboratories (NYSE: ABT) is not immune to the impact of tariffs on its medical device business. However, the company’s diversified business is tariff-resistant, and moves are being made to strengthen it further.
[content-module:CompanyOverview|NYSE:ABT]Those include a $500 million investment in two domestic manufacturing facilities expected to go live by year’s end.